01 Mar 2021 | EU | Biocon and Viatris announced that the CHMP has adopted a positive opinion recommending the marking...
Pearce IP BioBlast®: w/e 05 March 2021
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Emily Bristow
Emily provides broad paralegal services including litigation support services, legal research, IP monitoring and tracking services, and document management.
A self professed “legal junkie” she loves exploring legal arguments and is excited about new legal developments.
See Emily's full profile
Samsung Bioepis commenced Ph 1 trials for SB17 (proposed ustekinumab biosimilar)
Samsung Bioepis commenced Ph I trials for SB11 (proposed ustekinumab biosimilar).
Pearce IP BioBlast®: w/e 26 February 2021
23 Feb 2021 | In its Q4 2020 investor presentation, Fresenius Kabi announced it will launch its biosimilar adalimumab...
Pearce IP BioBlast®: w/e 19 February 2021
13 Feb 2021 | Saudi Arabia's Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution...
How medicine repurposing could unravel the pharma industry in Australia
TGA seeks consultation on issues relating to the registration of off-label medicines: Part 2
As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper...
Pearce IP features its Women in Science
In honour of UN International Day of Women and Girls in Science Last Thursday was the International Day of Women and...
Pearce IP BioBlast®: w/e 12 February 2021
04 Feb 2021 | Roche reported a huge erosion of its year on year CER growth in key areas, attributing this decline to...
TGA seeks consultation on issues relating to the registration of off-label use of medicines: Part 1
TGA has invited submissions on its consultation paper released last Thursday designed to facilitate indication...
Pearce IP BioBlast®: w/e 05 February 2021
29 Jan 21 | EU | The CHMP recommended 13 medicines for approval. Among the recommendations were two bevacizumab...
Pearce IP BioBlast®: w/e 29 January 2021
25 Jan 21 | Samsung Bioepis announced the opening of its new headquarters in Incheon. The building was complete in...
Pearce IP BioBlast®: w/e 22 January 2021
18 Jan 21 | Prestige Biopharma announced it is set for an IPO in early February 2021. The IPO is expected to be worth...
Pearce IP BioBlast™: w/e 15 January 2021
07 Jan 21 | ADQ announced it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon...
Pearce IP BioBlast™: w/e 08 January 2021
05 Jan 21 | EU | The Centre for Biosimilars reported a study presented at the 2020 San Antonio Breast Cancer Symposium...
Pearce IP BioBlast™: w/e 01 January 2021
27 Dec 20 | CN | Innovent announced China's NMPA has approved Byvasda® (biosimilar bevacizumab) for the additional...
Pearce IP BioBlast™: w/e 25 December 2020
21 Dec 20 | Celltrion announced Ph III trials of its proposed ustekinumab biosimilar CT-P43 will be completed by the...
Pearce IP BioBlast™: w/e 18 December 2020
12 Dec 20 | Biopharma supplier Alexion announced it will be acquired by AstraZeneca. The acquisition is expected to...